Humacyte Inc (HUMA) Stock Price, Quote & News

Latest News on HUMA

Jan 17, 2025, 10:30 AM EST - 16 hours ago

HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Jan 17, 2025, 9:15 AM EST - 17 hours ago

DEADLINE TODAY: The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Humacyte, Inc.

Jan 17, 2025, 5:14 AM EST - 21 hours ago

Humacyte, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - HUMA

Jan 16, 2025, 9:15 AM EST - 1 day ago

DEADLINE TOMORROW: Humacyte, Inc. Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm

Jan 15, 2025, 10:51 AM EST - 2 days ago

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte

Jan 15, 2025, 9:45 AM EST - 2 days ago

The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Humacyte Inc

Jan 14, 2025, 11:00 AM EST - 3 days ago

Humacyte, Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm

Jan 10, 2025, 6:32 PM EST - 7 days ago

Humacyte, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. January 17, 2025 Deadline to file Lead Plaintiff Motion

Jan 9, 2025, 5:45 AM EST - 8 days ago

Investors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA

Jan 6, 2025, 5:45 AM EST - 11 days ago

Humacyte, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - HUMA

Jan 3, 2025, 9:30 AM EST - 14 days ago

Humacyte Inc Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm

Jan 2, 2025, 12:15 PM EST - 15 days ago

The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Humacyte Inc.

Jan 2, 2025, 8:15 AM EST - 15 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte

Dec 31, 2024, 11:15 AM EST - 17 days ago

Humacyte, Inc. Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm

Dec 30, 2024, 11:00 AM EST - 18 days ago

The Schall Law Firm Encourages Shareholders With Losses To Join A Securities Fraud Case Against Humacyte Inc

Dec 29, 2024, 12:30 PM EST - 19 days ago

Humacyte, Inc. Is Being Sued For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law Firm

Dec 28, 2024, 11:45 AM EST - 20 days ago

The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Case Against Humacyte Inc

Dec 26, 2024, 11:30 AM EST - 22 days ago

The Schall Law Firm Urges Shareholder Participation In A Securities Fraud Case Against Humacyte Inc

Dec 26, 2024, 5:45 AM EST - 22 days ago

Humacyte, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA

Dec 24, 2024, 11:45 AM EST - 24 days ago

Humacyte, Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Invited To Contact The Schall Law Firm

Dec 21, 2024, 12:15 PM EST - 27 days ago

Humacyte Inc. Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Contact The Schall Law Firm

Dec 20, 2024, 12:35 PM EST - 4 weeks ago

Humacyte stock may fail to sustain today's gains: find out more

Dec 20, 2024, 11:15 AM EST - 4 weeks ago

The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Case Against Humacyte Inc.

Dec 20, 2024, 10:30 AM EST - 4 weeks ago

Humacyte's (HUMA) Insiders Sell Millions in Stock Amidst Lawsuit and Regulatory Troubles - Hagens Berman

Dec 20, 2024, 8:15 AM EST - 4 weeks ago

Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday?

Dec 19, 2024, 10:47 PM EST - 4 weeks ago

Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

Dec 19, 2024, 1:30 PM EST - 4 weeks ago

Humacyte, Inc. Is Being Sued For Violating Securities Laws And Affected Investors Are Invited To Contact The Schall Law Firm

Dec 19, 2024, 1:24 PM EST - 4 weeks ago

Humacyte's (HUMA) Insiders Sell Millions in Stock Amidst Lawsuit and Regulatory Troubles – Hagens Berman

Dec 18, 2024, 1:34 PM EST - 4 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. Lawsuit – HUMA

Dec 18, 2024, 10:04 AM EST - 4 weeks ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte

Dec 16, 2024, 3:36 PM EST - 4 weeks ago

Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman

Dec 16, 2024, 1:45 PM EST - 4 weeks ago

The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Case Against Humacyte Inc

Dec 15, 2024, 1:45 PM EST - 4 weeks ago

Humacyte, Inc. Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Contact The Schall Law Firm

Dec 14, 2024, 1:45 PM EST - 4 weeks ago

Market Cap	563.85M
Revenue (ttm)	0.00
Net Income (ttm)	-110.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,265,200
Avg Vol	5,155,432
Day's Range	N/A - N/A
Shares Out	125.86M
Stochastic %K	30%
Beta	1.32
Analysts	Strong Sell
Price Target	$13.14